Key result
LAAC linked to ~77% fewer recurrent strokes in AF patients failing anticoagulation.
Why the study?
Patients with nonvalvular atrial fibrillation who experience acute ischemic stroke despite oral anticoagulation have a high risk of recurrence even after changing anticoagulants, leaving the role of left atrial appendage closure unclear.
Does endovascular LAAC prevent recurrent acute ischemic stroke in NVAF patients who had AIS despite regular OAC use?
Cohort (n=29)
No
Does endovascular LAAC prevent recurrent acute ischemic stroke in NVAF patients who had AIS despite regular OAC use?
LAAC demonstrated a low annual rate of recurrent AIS (1.97%) in NVAF patients with prior AIS despite OAC, suggesting a potential role for LAAC in this high-risk population.
Answers are grounded in this paper and cite their sources.
LAAC was associated with low recurrent stroke rates in this cohort; leaves open need for randomized trials before practice change.
Background The occurrence of acute ischemic stroke (AIS) while regularly using oral anticoagulants (OAC) is an increasingly recognized problem among nonvalvular atrial fibrillation (NVAF) patients. Due to the high risk of AIS recurrence (reported 5.3-8.9 per 100 patient-years) even when the type of OAC is changed, we aimed to elucidate the potential role of left atrial appendage closure (LAAC) for prevention of recurrent strokes among AIS-despite-OAC patients. Methods Through retrospective review of electronic medical records of a single hospital system between January 2015 and October 2021, we collected baseline and follow-up data from consecutive NVAF patients who had AIS despite regular use of OAC per current guidelines and subsequently underwent endovascular LAAC for recurrent stroke prevention. The primary outcome measure was the occurrence of AIS after LAAC, and the safety outcome was symptomatic intracerebral hemorrhage (ICH). Results Twenty-nine patients had the endovascular LAAC specifically because of AIS-despite-OAC. The mean age was 73.4 ± 8.7, 13 were female (44.82%). Mean CHA 2 DS 2 -VASc score was 5.96 ± 1.32, with an expected AIS risk of 8.44 per 100 patient-years. Fourteen of the patients had two or more past AIS-despite-OAC. After LAAC, 27 patients (93.10%) were discharged on anticoagulant which was discontinued in 17 (58.62%) after transesophageal echocardiogram (TEE) at 6 weeks. Over a mean of 1.75±1.0 years follow-up after LAAC, only one patient had an AIS (incidence rate [IR] 1.97 per 100 patient-years) and one patient had a small ICH (IR 1.97 per 100 patient-years). Conclusions LAAC in patients who had AIS-despite-OAC demonstrated a low annual rate of recurrent AIS in our cohort (1.97%) compared both to the expected IR based on their CHA 2 DS 2 -VASc scores (8.44%) and to the recent large series of AIS-despite-OAC patients treated with OAC/aspirin only (5.3%-8.9%). These findings support randomized trials of LAAC in patients who have AIS-despite-OAC.
No takes yet. Share an insight, caveat, or question.
Fouks et al. (2023) conducted a cohort in Nonvalvular atrial fibrillation with acute ischemic stroke despite oral anticoagulation (n=29). Endovascular left atrial appendage closure (LAAC) vs. Expected incidence rate based on CHA2DS2-VASc scores was evaluated on Occurrence of acute ischemic stroke (AIS) after LAAC. Left atrial appendage closure in patients with atrial fibrillation and acute ischemic stroke despite anticoagulation demonstrated a low annual rate of recurrent stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: